Interleukin 17A inhibition is the effective therapeutic possibility in psoriatic arthritis. Comment to FUTIURE 5 study
Abstract
Interleukin 17 is a key modulator of inflammatory and destructive changes, especially in spondyloarthritis family. Interleukin 17A inhibition has proved to be an important treatment option in psoriatic arthritis.
FUTURE 5, the most extensive published study with biological treatment in active psoriatic arthritis showed a significant positive effect of secukinumab on disease activity, functional ability and skin psoriasis. Secukinumab treatment diminished the structural changes and increased the percentage of patients without x-ray changes.
Treatment significantly diminished the incidence of entesitis and dactylitis. Benefit from therapy had also patients after failure of antiTNF therapy.
Monitoring the side effects did not show the new risks of the treatment.